Page 26 - சிறப்பம்சங்கள் வழங்கப்பட்டது News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article CHICAGO, May 25, 2021 /PRNewswire/ In-depth analysis and data-driven insights on the impact of COVID-19 included in this global regenerative medicine market report. The regenerative medicine market is expected to grow at a CAGR of over 30% during the period 2020−2026. Key Highlights Offered in the Report:   The percentage share of gene therapy in the global market is more than 40% in 2020, which is expected to double by the year 2026. As CAR-T therapy is widely popular these days for the treatment of chronic cancers, the key vendors in the market are increasing their focus on developing the products in CAR-T cell therapy. In February 2021 US FDA approved Breyanzi, a CAR-T cell therapy product to treat adults with relapsed or refractory large B-cell lymphoma.

United statesSouth africaSaudi arabiaSouth koreaSibiono genetechChiesi farmaceuticiGilead sciencesRegenerative medicine companiesCancer care centersHuman stem cell instituteTakeda pharmaceuticalsRobust product pipeline of regenerative medicine companiesCare centersBristol myers squibbOsiris therapeuticsHighlights offered